Enanta Pharmaceuticals Company Insiders
ENTA Stock | USD 8.22 0.27 3.18% |
About 80 percent of Enanta Pharmaceuticals' insiders are selling. The analysis of the overall insider sentiment regarding Enanta Pharmaceuticals suggests that a fairly large number of insiders are terrified. Enanta Pharmaceuticals employs about 131 people. The company is managed by 11 executives with a total tenure of roughly 70 years, averaging almost 6.0 years of service per executive, having 11.91 employees per reported executive.
Jay Luly CEO CEO and President and Director |
Insider Sentiment 20
Mostly Selling
Selling | Buying |
Latest Trades
2025-02-12 | Jay R Luly | Acquired 45000 @ 5.69 | View | ||
2024-12-06 | Tara Lynn Kieffer | Disposed 2283 @ 8.06 | View | ||
2024-07-15 | Scott T Rottinghaus | Disposed 5375 @ 17.08 | View | ||
2024-07-11 | Scott T Rottinghaus | Disposed 4299 @ 15.07 | View | ||
2024-06-17 | Tara Lynn Kieffer | Disposed 7266 @ 12.33 | View |
Monitoring Enanta Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Enanta |
Enanta Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Enanta Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Enanta will maintain a workforce of about 130 employees by March 2025.Enanta Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.1775) % which means that it has lost $0.1775 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.691) %, meaning that it created substantial loss on money invested by shareholders. Enanta Pharmaceuticals' management efficiency ratios could be used to measure how well Enanta Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.34. The current year's Return On Capital Employed is expected to grow to -0.42. At present, Enanta Pharmaceuticals' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 5.6 M, whereas Total Assets are forecasted to decline to about 333.8 M.As of February 26, 2025, Common Stock Shares Outstanding is expected to decline to about 18.4 M. The current year's Net Loss is expected to grow to about (104.1 M)
Enanta Pharmaceuticals Workforce Comparison
Enanta Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 2,470. Enanta Pharmaceuticals holds roughly 131 in number of employees claiming about 5% of equities under Health Care industry.
Enanta Pharmaceuticals Profit Margins
The company has Profit Margin (PM) of (1.58) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.39) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.39.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.78 | 0.87 |
|
|
Enanta Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Enanta Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Enanta Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Enanta Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2025-03-01 | 1.1667 | 7 | 6 | 112,500 | 24,647 |
2024-12-01 | 0.6364 | 7 | 11 | 736,000 | 24,281 |
2024-09-01 | 0.2 | 1 | 5 | 5,375 | 18,786 |
2024-06-01 | 1.0 | 1 | 1 | 150,000 | 7,266 |
2024-03-01 | 1.75 | 14 | 8 | 124,323 | 12,498 |
2023-12-01 | 0.5 | 7 | 14 | 768,000 | 46,623 |
2023-06-01 | 1.0 | 1 | 1 | 6,667 | 6,667 |
2023-03-01 | 1.1905 | 25 | 21 | 315,853 | 193,880 |
2022-12-01 | 1.3846 | 18 | 13 | 582,648 | 88,468 |
2022-06-01 | 0.4615 | 6 | 13 | 83,344 | 170,168 |
2022-03-01 | 1.7059 | 29 | 17 | 156,111 | 118,669 |
2021-12-01 | 0.8636 | 19 | 22 | 385,270 | 85,597 |
2021-09-01 | 1.0 | 1 | 1 | 13,144 | 4,516 |
2021-03-01 | 3.0 | 9 | 3 | 126,193 | 16,021 |
2020-12-01 | 1.5 | 18 | 12 | 383,922 | 38,613 |
2020-09-01 | 1.0 | 1 | 1 | 1,666 | 1,666 |
2020-06-01 | 2.0 | 2 | 1 | 18,740 | 1,740 |
2020-03-01 | 2.0 | 16 | 8 | 74,681 | 19,787 |
2019-12-01 | 1.0 | 12 | 12 | 264,519 | 46,007 |
2019-09-01 | 1.0 | 1 | 1 | 5,000 | 5,000 |
2019-06-01 | 2.0 | 2 | 1 | 6,590 | 3,295 |
2019-03-01 | 0.9412 | 32 | 34 | 224,116 | 195,955 |
2018-12-01 | 1.2222 | 11 | 9 | 193,500 | 55,500 |
2018-09-01 | 0.1538 | 4 | 26 | 17,363 | 69,873 |
2018-06-01 | 0.2105 | 4 | 19 | 15,825 | 68,360 |
2018-03-01 | 1.7273 | 19 | 11 | 113,774 | 36,161 |
2017-06-01 | 4.0 | 4 | 1 | 57,125 | 29,274 |
2017-03-01 | 1.5714 | 11 | 7 | 51,320 | 20,711 |
2016-12-01 | 13.0 | 13 | 1 | 347,500 | 13,921 |
2016-06-01 | 1.5 | 3 | 2 | 67,145 | 66,645 |
2016-03-01 | 2.5714 | 18 | 7 | 199,339 | 133,705 |
2015-12-01 | 1.375 | 11 | 8 | 334,200 | 82,200 |
2015-06-01 | 0.2 | 1 | 5 | 90,000 | 54,000 |
2015-03-01 | 1.3333 | 12 | 9 | 90,404 | 100,544 |
2014-12-01 | 0.5833 | 7 | 12 | 243,805 | 47,055 |
2014-09-01 | 0.2 | 2 | 10 | 12,149 | 61,149 |
2014-06-01 | 0.1 | 1 | 10 | 82,500 | 35,000 |
2014-03-01 | 0.3077 | 16 | 52 | 649,451 | 1,562,131 |
2013-12-01 | 0.2059 | 7 | 34 | 199,280 | 338,369 |
2013-09-01 | 0.2 | 1 | 5 | 84,265 | 98,565 |
2013-03-01 | 0.4714 | 33 | 70 | 9,366,983 | 36,002,188 |
Enanta Pharmaceuticals Notable Stakeholders
An Enanta Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Enanta Pharmaceuticals often face trade-offs trying to please all of them. Enanta Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Enanta Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Jay Luly | CEO and President and Director | Profile | |
Paul Mellett | CFO and Sr. VP of Fin. and Admin. | Profile | |
Yat Or | Chief Scientific Officer and Sr. VP of RandD | Profile | |
Nathaniel JD | General VP | Profile | |
Scott MD | Senior Officer | Profile | |
Nathalie MD | Consultant | Profile | |
Jennifer Viera | Executive Communications | Profile | |
Tara Kieffer | Senior Development | Profile | |
Brendan Luu | Senior Development | Profile | |
Matthew JD | Chief Secretary | Profile | |
Scott Rottinghaus | VP Officer | Profile |
About Enanta Pharmaceuticals Management Performance
The success or failure of an entity such as Enanta Pharmaceuticals often depends on how effective the management is. Enanta Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Enanta management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Enanta management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.35) | (0.34) | |
Return On Capital Employed | (0.44) | (0.42) | |
Return On Assets | (0.35) | (0.34) | |
Return On Equity | (1.04) | (0.98) |
Please note, the presentation of Enanta Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Enanta Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Enanta Pharmaceuticals' management manipulating its earnings.
Enanta Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Enanta Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Enanta Pharmaceuticals within its industry.Enanta Pharmaceuticals Manpower Efficiency
Return on Enanta Pharmaceuticals Manpower
Revenue Per Employee | 516.3K | |
Revenue Per Executive | 6.1M | |
Net Loss Per Employee | 885.8K | |
Net Loss Per Executive | 10.5M | |
Working Capital Per Employee | 1.8M | |
Working Capital Per Executive | 22M |
Complementary Tools for Enanta Stock analysis
When running Enanta Pharmaceuticals' price analysis, check to measure Enanta Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enanta Pharmaceuticals is operating at the current time. Most of Enanta Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Enanta Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enanta Pharmaceuticals' price. Additionally, you may evaluate how the addition of Enanta Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Stocks Directory Find actively traded stocks across global markets | |
Transaction History View history of all your transactions and understand their impact on performance | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |